The presentation of preclinical data for Qualigen Therapeutics' Pan-RAS Inhibitor Platform at the 2023 ASCO Meeting demonstrates the company's progress in developing a potentially significant therapeutic platform. This news may attract investor interest and positively impact the stock price of QLGN in the short term.